According to a new report LAMEA Cartilage Repair Market, published by KBV research, the LAMEA Cartilage Repair Market would witness market growth of 10.2% CAGR during the forecast period (2018 – 2024).
The Brazil market would dominate the LAMEA Cell-Based Market by Country by 2024, growing at a CAGR of 9 % during the forecast period. The Argentina market is expected to witness a CAGR of 10.4% during (2018 - 2024). Additionally, The UAE market is expected to witness a CAGR of 8.4% during (2018 - 2024).
The Fibrocartilage market dominated the LAMEA Cartilage Repair Market by Application in 2017. The Hyaline Cartilage market is expected to witness a CAGR of 9.5% during (2018 - 2024).
The Intrinsic Repair Stimulus market dominated the UAE Cartilage Repair Market by Treatment Type in 2017, and would achieve a market value of $59.1 million by 2024, growing at a CAGR of 8.5 % during the forecast period. The Palliative market is expected to witness highest CAGR of 9.7% during (2018 - 2024).
Full Report: https://www.kbvresearch.com/lamea-cartilage-repair-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of B. Braun Melsungen AG, Zimmer Biomet, Johnson and Johnson, Smith & Nephew Plc., Stryker Corporation, Vericel Corporation, Osiris Therapeutics Inc., Arthrex, Inc., Collagen Solutions Plc., and Anika Therapeutics, Inc.
LAMEA Cartilage Repair Market Segmentation
By Modality
By Treatment type
By Application
By Site outlook
By Country
Companies Profiled
Unique Offerings from KBV Research
Related Reports:
Unique Offerings 
